Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis

被引:6
作者
Oikonomou, Theodora [1 ]
Goulis, Ioannis [1 ]
Ntogramatzi, Fani [2 ]
Athanasiadou, Zoi [2 ]
Vagdatli, Eleni [2 ]
Akriviadis, Evangelos [1 ]
Cholongitas, Evangelos [3 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Gen Hosp, Dept Internal Med 4, Thessaloniki 54642, Greece
[2] Hippokrateion Hosp, Dept Biochem, Thessaloniki 54642, Greece
[3] Natl & Kapodistrian Univ Athens, Sch Med, Laiko Gen Hosp, Dept Internal Med 1, Agiou Thoma 17, Athens 11527, Greece
关键词
Decompensated cirrhosis; Galectin-3; Kidney; Renal function; Liver; Cirrhosis; Prognosis; LIVER; SURVIVAL; MODEL;
D O I
10.1016/j.dld.2019.05.030
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Newly introduced galectin-3 (gal-3) has been associated to impaired renal function. Gal-3 may become prognostic biomarker in hepatic diseases. Aim: To investigate the association of gal-3 with prognosis and renal function in patients with stable decompensated cirrhosis. Method: We studied prospectively 100 stable decompensated patients in our Department between 2010 and 2017. We measured gal-3 in serum samples. Patients' renal function was assessed using (51)Chromium-EDTA ("true GFR"). Results: Seventy patients (70%) survived and 30 died (n = 16) or underwent LT (n = 14). Twenty nine patients (29%) had normal gal-3, 71 (71%) had >= 11.7 ng/mL; they differed significantly regarding mean "true"-GFR: 90 +/- 20 mL/min vs. 76 +/- 26 mL/min, p = 0.03 and mean creatinine: 0.83 +/- 0.14 mg/dL vs. 0.97 +/- 0.4 mg/dL, p = 0.05. Median gal-3 levels were 17.5 ng/mL (range 4.9-76.5 ng/mL); 49 patients with gal-3 >= 17.5 ng/mL had significantly higher MELD score, (15 +/- 5 vs. 13 +/- 4, p = 0.02) and worse "true" GFR (74 vs. 85 mL/min, p = 0.04). Gal-3 had good performance in predicting "true"-GFR < 60 mL/min; AUC: 0.71, 95%CI [0.58-0.85], best cut off value 17.5 ng/mL. Kaplan-Meier analysis, using median gal-3 (17.5 ng/mL) revealed different survival time for our patients (log-rank p = 0.04). Conclusion: Gal-3 proved trustworthy marker of established chronic kidney disease, with predictive ability in stable decompensated cirrhosis. Gal-3 came also a significant factor for our patients' outcome. (c) 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1692 / 1697
页数:6
相关论文
共 22 条
[11]  
Group KDIGOKCW, 2013, KIDNEY INT SUPPL, V3, P1
[12]  
Gudowska M, 2015, ANN CLIN LAB SCI, V45, P669
[13]   A METHOD OF COMPARING THE AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES DERIVED FROM THE SAME CASES [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1983, 148 (03) :839-843
[14]  
Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.3.CO
[15]  
2-S
[16]   A model to predict survival in patients with end-stage liver disease [J].
Kamath, PS ;
Wiesner, RH ;
Malinchoc, M ;
Kremers, W ;
Therneau, TM ;
Kosberg, CL ;
D'Amico, G ;
Dickson, ER ;
Kim, WR .
HEPATOLOGY, 2001, 33 (02) :464-470
[17]   A New Equation to Estimate Glomerular Filtration Rate [J].
Levey, Andrew S. ;
Stevens, Lesley A. ;
Schmid, Christopher H. ;
Zhang, Yaping ;
Castro, Alejandro F., III ;
Feldman, Harold I. ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Greene, Tom ;
Coresh, Josef .
ANNALS OF INTERNAL MEDICINE, 2009, 150 (09) :604-612
[18]   Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis [J].
Pejnovic, Nada ;
Jeftic, Ilija ;
Jovicic, Nemanja ;
Arsenijevic, Nebojsa ;
Lukic, Miodrag L. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (44) :9706-9717
[19]  
Pipili Chrysoula, 2014, World J Gastrointest Pharmacol Ther, V5, P156, DOI 10.4292/wjgpt.v5.i3.156
[20]   TRANSECTION OF ESOPHAGUS FOR BLEEDING ESOPHAGEAL VARICES [J].
PUGH, RNH ;
MURRAYLY.IM ;
DAWSON, JL ;
PIETRONI, MC ;
WILLIAMS, R .
BRITISH JOURNAL OF SURGERY, 1973, 60 (08) :646-649